FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1860778828> ?p ?o ?g. }

• W1860778828 endingPage "719" @default.
• W1860778828 startingPage "711" @default.
• W1860778828 abstract "The tricyclic indole compound, [(18)F]GE-180 has been previously identified as a promising positron emission tomography (PET) imaging agent of the translocator protein (TSPO) with the potential to aid in the diagnosis, prognosis and therapy monitoring of degenerative neuroinflammatory conditions such as multiple sclerosis. [(18)F]GE-180 was first identified and evaluated as a racemate, but subsequent evaluations of the resolved enantiomers have shown that the S-enantiomer has a higher affinity for TSPO and an improved in vivo biodistribution performance, in terms of higher uptake in specific brain regions and good clearance (as described previously). Here we describe the additional biological evaluations carried out to confirm the improved performance of the S-enantiomer and including experiments which have demonstrated the stability of the chiral centre to chemical and biological factors.GE-180 and the corresponding radiolabelling precursor were separated into single enantiomers using semi-preparative chiral supercritical fluid chromatography (SFC). A detailed comparison of the individual enantiomers and the racemate was carried out in a number of biological studies. TSPO binding affinity was assessed using a radioligand binding assay. Incubation with rat hepatic S9 fractions was used to monitor metabolic stability. In vivo biodistribution studies up to 60 min post injection (PI) in naïve rats were carried out to monitor uptake and clearance. Achiral and chiral in vivo metabolite detection methods were developed to assess the presence of metabolite/s in plasma and brain samples, with the chiral method also determining potential racemisation at the chiral centre.Evaluation of the chiral stability of the two enantiomers to metabolism by rat S9 fractions, showed no racemisation of enantiomers. There were notable differences in the biodistribution between the racemate and the R- and S-enantiomers. All compounds had similar initial brain uptake between 0.99 and 1.01% injected dose (id) at 2 min PI, with S-[(18)F]GE-180 showing significantly greater retention than the R-enantiomer at 10 and 30 min PI (P<0.05). S-[(18)F]GE-180 uptake to the TSPO-expressing olfactory bulbs was 0.45% id (SD ± 0.17) at 30 min PI in comparison to RS-[(18)F]GE-180 or R-[(18)F]GE-180 levels of 0.41% id ± 0.09 and 0.23% id ± 0.02 respectively, at the same timepoint (P > 0.05). The signal-to-noise ratio (ratio olfactory bulb to striata binding) were similar for both RS-[(18)F]GE-180 and S-[(18)F]GE-180 (3.2 and 3.4 respectively). Initial uptake to the lungs (an organ with high TSPO expression) was more than 3-fold greater with S-[(18)F]GE-180 than R-[(18)F]GE-180, and significantly higher at 10 and 30 min PI (P < 0.05). Furthermore lung uptake of S-[(18)F]GE-180 at 2 and 10 min PI was also significant when compared to the racemate (P < 0.05). The majority of the radioactivity in the rat brain following administration of RS-[(18)F]GE-180 or S-[(18)F]GE-180 was due to the presence of the parent compound (91% ± 1.5 and 94% ± 2.0 of total radioactivity at 60 min PI respectively). In contrast at 60 min PI for the plasma samples, the parent compounds accounted for only 28% ± 1.2 and 21% ± 4.6 of total radioactivity for RS-[(18)F]GE-180 and S-[(18)F]GE-180 respectively. Chiral assessment confirmed that the S-enantiomer was chirally stable in vivo, with no stereochemical conversion in brain and plasma samples up to 60 min PI.Developing racemic radiotracers, as for racemic therapeutics, is a considerable challenge due to differences of the enantiomers in pharmacokinetics, efficacy and potential toxicity. We have shown that the enantiomers of the promising racemic PET ligand [(18)F]GE-180 do not share identical performance, with S-[(18)F]GE-180 demonstrating higher TSPO affinity, higher brain uptake and better retention to the high TSPO-expressing lungs. Furthermore, S-[(18)F]GE-180 has also been shown to be enantiomerically stable in vivo, with no observed conversation of the eutomer to the distomer. As a single enantiomer, S-[(18)F]GE-180 retains the beneficial characteristics of the racemate and is a promising imaging agent for imaging neuroinflammation in vivo." @default.
• W1860778828 created "2016-06-24" @default.
• W1860778828 creator A5006053452 @default.
• W1860778828 creator A5006333227 @default.
• W1860778828 creator A5038751537 @default.
• W1860778828 creator A5048500849 @default.
• W1860778828 creator A5049673128 @default.
• W1860778828 creator A5059872351 @default.
• W1860778828 creator A5062093717 @default.
• W1860778828 creator A5069652443 @default.
• W1860778828 creator A5079242523 @default.
• W1860778828 creator A5085428054 @default.
• W1860778828 creator A5089291325 @default.
• W1860778828 date "2015-09-01" @default.
• W1860778828 modified "2023-09-26" @default.
• W1860778828 title "Exploration of the impact of stereochemistry on the identification of the novel translocator protein PET imaging agent [18F]GE-180" @default.
• W1860778828 cites W1965133186 @default.
• W1860778828 cites W1965955338 @default.
• W1860778828 cites W1967698682 @default.
• W1860778828 cites W1979007089 @default.
• W1860778828 cites W1998667858 @default.
• W1860778828 cites W2009152709 @default.
• W1860778828 cites W2009208296 @default.
• W1860778828 cites W2012191973 @default.
• W1860778828 cites W2017045422 @default.
• W1860778828 cites W2031648971 @default.
• W1860778828 cites W2034946478 @default.
• W1860778828 cites W2041899560 @default.
• W1860778828 cites W2053801699 @default.
• W1860778828 cites W2060220993 @default.
• W1860778828 cites W2077541192 @default.
• W1860778828 cites W2084971977 @default.
• W1860778828 cites W2087384563 @default.
• W1860778828 cites W2103312948 @default.
• W1860778828 cites W2117278034 @default.
• W1860778828 cites W2159239201 @default.
• W1860778828 cites W2159969591 @default.
• W1860778828 cites W2161491363 @default.
• W1860778828 cites W2170880874 @default.
• W1860778828 doi "https://doi.org/10.1016/j.nucmedbio.2015.05.004" @default.
• W1860778828 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26072270" @default.
• W1860778828 hasPublicationYear "2015" @default.
• W1860778828 type Work @default.
• W1860778828 sameAs 1860778828 @default.
• W1860778828 citedByCount "17" @default.
• W1860778828 countsByYear W18607788282016 @default.
• W1860778828 countsByYear W18607788282017 @default.
• W1860778828 countsByYear W18607788282018 @default.
• W1860778828 countsByYear W18607788282019 @default.
• W1860778828 countsByYear W18607788282020 @default.
• W1860778828 countsByYear W18607788282021 @default.
• W1860778828 countsByYear W18607788282022 @default.
• W1860778828 countsByYear W18607788282023 @default.
• W1860778828 crossrefType "journal-article" @default.
• W1860778828 hasAuthorship W1860778828A5006053452 @default.
• W1860778828 hasAuthorship W1860778828A5006333227 @default.
• W1860778828 hasAuthorship W1860778828A5038751537 @default.
• W1860778828 hasAuthorship W1860778828A5048500849 @default.
• W1860778828 hasAuthorship W1860778828A5049673128 @default.
• W1860778828 hasAuthorship W1860778828A5059872351 @default.
• W1860778828 hasAuthorship W1860778828A5062093717 @default.
• W1860778828 hasAuthorship W1860778828A5069652443 @default.
• W1860778828 hasAuthorship W1860778828A5079242523 @default.
• W1860778828 hasAuthorship W1860778828A5085428054 @default.
• W1860778828 hasAuthorship W1860778828A5089291325 @default.
• W1860778828 hasBestOaLocation W18607788281 @default.
• W1860778828 hasConcept C126322002 @default.
• W1860778828 hasConcept C150903083 @default.
• W1860778828 hasConcept C185592680 @default.
• W1860778828 hasConcept C202751555 @default.
• W1860778828 hasConcept C207001950 @default.
• W1860778828 hasConcept C2775842073 @default.
• W1860778828 hasConcept C2776791281 @default.
• W1860778828 hasConcept C2776914184 @default.
• W1860778828 hasConcept C2777477808 @default.
• W1860778828 hasConcept C2777807558 @default.
• W1860778828 hasConcept C2989005 @default.
• W1860778828 hasConcept C43617362 @default.
• W1860778828 hasConcept C486523 @default.
• W1860778828 hasConcept C55493867 @default.
• W1860778828 hasConcept C67847695 @default.
• W1860778828 hasConcept C71240020 @default.
• W1860778828 hasConcept C71924100 @default.
• W1860778828 hasConcept C86803240 @default.
• W1860778828 hasConcept C87753298 @default.
• W1860778828 hasConceptScore W1860778828C126322002 @default.
• W1860778828 hasConceptScore W1860778828C150903083 @default.
• W1860778828 hasConceptScore W1860778828C185592680 @default.
• W1860778828 hasConceptScore W1860778828C202751555 @default.
• W1860778828 hasConceptScore W1860778828C207001950 @default.
• W1860778828 hasConceptScore W1860778828C2775842073 @default.
• W1860778828 hasConceptScore W1860778828C2776791281 @default.
• W1860778828 hasConceptScore W1860778828C2776914184 @default.
• W1860778828 hasConceptScore W1860778828C2777477808 @default.
• W1860778828 hasConceptScore W1860778828C2777807558 @default.
• W1860778828 hasConceptScore W1860778828C2989005 @default.
• W1860778828 hasConceptScore W1860778828C43617362 @default.
• W1860778828 hasConceptScore W1860778828C486523 @default.

• next